Today: 13 June 2026
Bank of America stock falls on Trump credit-card rate cap talk as CPI, earnings near
13 January 2026
2 mins read

Bank of America stock falls on Trump credit-card rate cap talk as CPI, earnings near

New York, January 12, 2026, 17:49 EST — After-hours

Shares of Bank of America Corp fell Monday, dragged down by President Donald Trump’s effort to limit credit card interest rates. BAC dipped about 1.2% to $55.19 in after-hours trading, after earlier touching a low of $54.15. Trading volume hit roughly 45.8 million shares for the day.

Credit cards generate strong profits for big lenders, but a cap could wipe out a revenue stream investors count on. The debate is intensifying ahead of a heavy slate of bank earnings on Wall Street.

Financials took a hit while the broader market eked out small gains. The S&P 500 ETF SPY rose about 0.2%, yet the Financial Select Sector SPDR Fund XLF fell 0.8%. The bank-heavy KBE declined roughly 1.3%.

On Friday, Trump pitched a one-year freeze on credit card interest rates, capping them at 10% starting Jan. 20. He didn’t, however, clarify how this would be enforced, Reuters reported. UBS Global analysts flagged that “It would take an Act of Congress for such rate caps.” Meanwhile, J.P. Morgan’s Vivek Juneja cautioned it could push consumers toward “more expensive debt” outside traditional banks. Shares of Bank of America, JPMorgan, Citigroup, and Wells Fargo dropped in early trading. Card issuers and payment processors including Synchrony, Capital One, Visa, and Mastercard also saw their stocks dip, according to the report. Reuters

Rate uncertainty is creeping back in. After December’s jobs report, J.P. Morgan and several other banks pushed their forecasts for Federal Reserve rate cuts out to mid-2026. But BofA Global Research held firm, sticking with its call for cuts around June-July, Reuters reported.

Bank of America will report its fourth-quarter 2025 earnings before the market opens on Wednesday, Jan. 14. The announcement is set for around 6:45 a.m. ET, with an investor call to follow at 8:30 a.m., the bank said.

Investors are zeroing in on the bank’s consumer credit outlook, especially card charge-offs — the losses logged when borrowers default. They’ll also be watching for clues on whether credit demand holds firm. Expense guidance and any subtle signals about buyback plans might prove just as important.

Net interest income—the gap between earnings on loans and expenses on deposits—still drives most of the group’s profits. But a sudden rise in deposit costs can quickly erase any gains from better trading or investment banking fees.

Options point to a choppier reaction to the earnings than usual. TipRanks shows the implied move in BAC sits near 3.8% up or down, a number pulled directly from option prices.

On Monday, BofA Finance LLC, backed by a guarantee from Bank of America, filed a prospectus for an offering of trigger callable yield notes linked to the S&P 500 and the S&P 500 Equal Weight Index, set to mature in January 2028.

There’s a chance things could swing the other way. If the rate-cap debate gains political traction, lenders may tighten credit limits and tweak pricing. That would likely slow growth, even as it shields their margins.

Tuesday at 8:30 a.m. ET brings the U.S. CPI data for December, a key read before the bank earnings kick off. This report might rattle rate expectations and shake up bank valuations. Following that, attention turns to Bank of America’s Jan. 14 earnings and its updates on cards, credit, and expenses.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal
Previous Story

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop